Cryoglobulinemic vasculitis
Learn about Cryoglobulinemic vasculitis, its reported features, relevant specialists, and questions to discuss at a medical consultation.
Also known as: Essential cryoglobulinemia; Essential mixed cryoglobulinemia; Mixed cryoglobulinemia; Primary cryoglobulinemia
The sources compiled here do not cover: diagnosis, treatment, prevention, prognosis. Ask the treating doctor about these.
What it is
From: Orphanet
A rare immune complex-mediated vasculitis characterized by the presence of circulating cryoprecipitable immune complexes in the serum, manifesting clinically with the classical triad of purpura, weakness and arthralgia.
Reported clinical features and what the terms mean
The following findings are associated with this condition in Orphanet. They are not a checklist for diagnosing yourself, and they do not all occur in every affected person. Some are examination, imaging or laboratory findings that cannot be recognised at home.
The frequency labels describe how often a finding was reported among people with the condition in the source. They do not give the chance that a person with that symptom has the condition. Definitions below reproduce HPO terminology; they explain the term, not the likely severity in an individual.
- Circulating immune complexes · Very frequent (99-80%)
- Persistence of immune complexes in the blood circulation.
- Cryoglobulinemia · Very frequent (99-80%)
- Increased level of cryoglobulins in the blood. Cryoglobulins are abnormal immunoglobulins, especially IGG or IGM, that precipitate spontaneously when serum is cooled below 37 degrees Celsius.
- Cutis marmorata · Very frequent (99-80%)
- A reticular discoloration of the skin with cyanotic (reddish-blue appearing) areas surrounding pale central areas due to dilation of capillary blood vessels and stagnation of blood within the vessels. Cutis marmorata generally occurs on the legs, arms and trunk and is often more severe in cold weather.
- Fever · Very frequent (99-80%)
- Body temperature elevated above the normal range.
- Mediastinal lymphadenopathy · Very frequent (99-80%)
- Swelling of lymph nodes within the mediastinum, the central compartment of the thoracic cavities that contains the heart and the great vessels, the esophagus, and trachea and other structures including lymph nodes.
- Muscle weakness · Very frequent (99-80%)
- Reduced strength of muscles.
- Petechiae · Very frequent (99-80%)
- Petechiae are pinpoint-sized reddish/purple spots, resembling a rash, that appear just under the skin or a mucous membrane when capillaries have ruptured and some superficial bleeding into the skin has happened. This term refers to an abnormally increased susceptibility to developing petechiae.
- Purpura · Very frequent (99-80%)
- Purpura (from Latin: purpura, meaning purple) is the appearance of red or purple discolorations on the skin that do not blanch on applying pressure. They are caused by bleeding underneath the skin. This term refers to an abnormally increased susceptibility to developing purpura. Purpura are larger than petechiae.
- Skin ulcer · Very frequent (99-80%)
- A discontinuity of the skin exhibiting complete loss of the epidermis and often portions of the dermis and even subcutaneous fat.
- Vasculitis · Very frequent (99-80%)
- Inflammation of blood vessel.
- Abdominal pain · Frequent (79-30%)
- An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) and perceived to originate in the abdomen.
- Abnormality of the liver · Frequent (79-30%)
- An abnormality of the liver.
- Arthralgia · Frequent (79-30%)
- Joint pain.
- Arthritis · Frequent (79-30%)
- Inflammation of a joint.
Other findings in the same source
From: Orphanet
Additional reported features include Gangrene (Frequent (79-30%)); Glomerulopathy (Frequent (79-30%)); Hematuria (Frequent (79-30%)); Hepatomegaly (Frequent (79-30%)); Mononeuropathy (Frequent (79-30%)); Myalgia (Frequent (79-30%)); Peripheral neuropathy (Frequent (79-30%)); Proteinuria (Frequent (79-30%)); Renal insufficiency (Frequent (79-30%)); Splenomegaly (Frequent (79-30%)). This is a selected summary, not a complete description of the condition.
When it may begin
From: Orphanet
All ages
Inheritance in the source
From: Orphanet
Not applicable
Frequency and the population described
From: Orphanet
Point prevalence: 1-9 / 100 000; United States; Value and class.
Which doctor should you see?
The suggested department for discussing Cryoglobulinemic vasculitis is Rheumatology, with a rheumatologist as the relevant type of clinician. General physician / Family Medicine; paediatrician for children. Referral depends on symptoms.
This is an editorial referral starting point. The appropriate clinic depends on the person’s age, symptoms, previous diagnosis and local services. The first clinician can decide whether another specialty or a team is needed; a department label does not confirm the diagnosis.
How to prepare for an assessment
Bring a short timeline of the main symptoms: when they first appeared, whether they are constant or episodic, what seems to change them, and how they affect daily activities. Include previous reports, discharge summaries, current medicines and supplements, allergies, and any relevant family history. A dated record is more useful than trying to match every feature in an online article.
Ask the clinician what is already established and what remains uncertain. If a test is suggested, ask what question it answers, what its limitations are and how the result would change the next step. The information here is not an instruction to arrange every possible test. In children, bring growth, developmental and school information if it is relevant to the concern.
- Are the findings inflammatory, structural or due to another mechanism?
- Is there evidence that other organs need assessment?
- How will function and any treatment-related risks be monitored?
Treatment discussions and follow-up
The material gathered for this draft does not provide a complete condition-specific treatment pathway for Cryoglobulinemic vasculitis. That gap does not mean that treatment is unavailable. A clinician needs to establish the diagnosis and review current guidance before recommending medicines, procedures, rehabilitation or other support.
Before leaving the appointment, clarify the next review date, who will communicate results, and whom to contact if the situation changes. Discuss difficulties with sleep, work, school, mobility, eating or emotional wellbeing when these are relevant. Practical support may require coordination between the treating clinician and other services.
The collected references do not establish a complete prevention or long-term outlook section for this entry. Missing information should not be interpreted as proof that prevention is impossible or that a particular outcome is inevitable. Ask what is known for the exact subtype, stage and personal circumstances, and which uncertainties remain.
When to seek emergency help
Severe breathing difficulty, collapse, new stroke-like symptoms, a seizure that is prolonged or repeated without recovery, uncontrolled major bleeding, or an immediate risk of self-harm require emergency help. In India, call 112 or reach the nearest emergency department. This is a general, non-exhaustive warning list; it is not a condition-specific triage tool.
This condition is usually assessed by a rheumatologist. Every profile shows the doctor’s registration and what has been checked.
Sources
- Orphanet — Cryoglobulinemic vasculitis — Orphadata Science, CC BY 4.0
- Human Phenotype Ontology Consortium — terminology definitions — HPO licence; definitions reproduced without alteration
- Government of India — Emergency Response Support System — Official reference for India emergency number
Source: MedlinePlus, National Library of Medicine. Orphadata Science: Free access data from Orphanet. © INSERM 1999; July 2026 data, CC BY 4.0. This product uses the Human Phenotype Ontology (hp/releases/2026-09-01). Only sources listed for this article apply. Source material has been selected and arranged; HPO definitions are reproduced without alteration. No source organisation endorses this compilation. Köhler S et al. The Human Phenotype Ontology project: linking molecular biology and disease through phenotype data. Nucleic Acids Research 2014;42(D1):D966–D974. doi:10.1093/nar/gkt1026.
General information, not advice about your situation. Errors can be reported through the corrections process. Reference TDI-C-0679.